Sign In
Buy CTLT
$63.49
+0 (+0%)
At Close: Mar 14, 2025
Catalent (CTLT) Up on Encouraging Pre-Filled Syringe Potential
09:46am, Thursday, 16'th Nov 2023
Catalent (CTLT) expects the demand for its pre-filled syringes to improve going forward. The company anticipates the majority of its pre-filled syringe production capacity to be booked until fiscal 20
Syringe Maker Catalent Anticipates Boost From Demand for Injectable Weight-Loss Drugs
05:55pm, Wednesday, 15'th Nov 2023
Syringe maker Catalent (CTLT) said soaring demand for injectable weight-loss drugs could lead to big revenue gains, and shares surged over 11%.
Catalent, Inc. (CTLT) Q1 2024 Earnings Call Transcript
04:39pm, Wednesday, 15'th Nov 2023
Catalent, Inc. (NYSE:CTLT ) Q1 2024 Earnings Call Transcript November 15, 2023 8:15 AM ET Company Participants Paul Surdez - Vice President of Investor Relations John Greisch - Executive Chair of Boar
Catalent doubles down on full year outlook as preliminary 1Q earnings beat estimates
12:33pm, Wednesday, 15'th Nov 2023
Catalent shares added more than 11% after the contract drugmaker's preliminary first quarter earnings topped expectations and it reaffirmed its full-year fiscal 2024 guidance. For the quarter ended i
Catalent beats quarterly revenue estimates
07:15am, Wednesday, 15'th Nov 2023
Contract drug manufacturer Catalent on Wednesday beat Wall Street estimates for quarterly revenue as production showed signs of improvement on the back of a change in management.
Market Movers at Noon Tuesday: Catalent (CTLT), VF Corp (VFC), Arista (ANET), Leidos (LDOS)
12:55pm, Tuesday, 31'st Oct 2023
Tuesday morning economic news did not include big changes in either the consumer confidence index, down about 1.5 points month over month but still above 100, or the employment cost index, up by 1.1%,
Catalent Remains Overvalued
01:08pm, Wednesday, 04'th Oct 2023
Catalent, Inc.'s revenue and scale have suffered due to the decline in vaccine deliveries, particularly in its Biologics segment. The company reported a 3% increase in revenue for the quarter-ended Ju
3 Reasons to Hold Catalent (CTLT) Stock in Your Portfolio
12:02pm, Wednesday, 27'th Sep 2023
Catalent's (CTLT) product and service launches and a slew of strategic deals raise optimism about the stock.
Activist Elliott makes inroads at Catalent to build value. Here's what could happen next
08:35am, Saturday, 16'th Sep 2023
Elliott recently entered a cooperation agreement with Catalent. This could pave the way for some major changes at the pharmaceutical company.
Catalent gets NYSE notice that it's not in compliance with listing rules over late 10-K filing
07:22am, Friday, 15'th Sep 2023
Drug manufacturer Catalent Inc. CTLT, +1.74% said Friday it has received a notice from the New York Stock Exchange informing it that's it's not in compliance with listing rules due to a delay in filin
Why Catalent Stock Zoomed 12% Higher This Week
06:35pm, Friday, 01'st Sep 2023
The company delivered a better-than-expected quarterly earnings report. It beat on revenue, and only narrowly missed on earnings.
Catalent (CTLT) Gains Post Deal With Elliott and Earnings Report
03:02pm, Wednesday, 30'th Aug 2023
Catalent's (CTLT) deal with Elliott and earnings report boost its shares. The company will likely improve its value and growth with the agreement and its strategic investments.
Why Catalent Stock Surged Nearly 5% Higher Today
05:04pm, Tuesday, 29'th Aug 2023
The contract drug manufacturer posted steep declines in key fundamentals in its fiscal fourth quarter. Still, it booked more revenue than analysts expected; guidance also topped expectations.
Catalent, Inc. (CTLT) Q4 2023 Earnings Call Transcript
04:02pm, Tuesday, 29'th Aug 2023
Catalent, Inc. (NYSE:CTLT ) Q4 2023 Earnings Conference Call August 29, 2023 8:15 AM ET Company Participants Paul Surdez - Vice President, Investor Relations John Greisch - Executive Chair, Board Ales
Catalent (CTLT) Preliminary Q4 Revenues Dampened by Lower Sales
03:02pm, Tuesday, 29'th Aug 2023
Catalent (CTLT) records lower revenues in Biologics segment in its fourth-quarter fiscal 2023, resulting in overall soft preliminary performance.
